Stockscreener 앱 받기
10.97
0.73%
-0.010
전일 마감가:
$10.96
열려 있는:
$10.92
하루 거래량:
22,713
Relative Volume:
0.03
시가총액:
$233.66M
수익:
$66.59M
순이익/손실:
$-104.93M
주가수익비율:
-2.2162
EPS:
-4.95
순현금흐름:
$-96.48M
1주 성능:
+3.62%
1개월 성능:
+5.32%
6개월 성능:
+82.86%
1년 성능:
-0.64%
1일 변동 폭
$10.78
$11.18
1주일 범위
$10.30
$11.45
52주 변동 폭
$4.09
$15.34
Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile
명칭
Enanta Pharmaceuticals Inc
전화
617 607 0800
주소
4 KINGSBURY AVENUE, WATERTOWN, MA
ENTA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ENTA
Enanta Pharmaceuticals Inc
|
10.93 | 316.23M | 66.59M | -104.93M | -96.48M | -4.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.19 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
633.67 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.81 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
821.48 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
181.32 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-01 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-07-28 | 재개 | H.C. Wainwright | Buy |
| 2023-08-09 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-08-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-12-09 | 개시 | H.C. Wainwright | Buy |
| 2022-07-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2022-06-01 | 업그레이드 | Evercore ISI | Underperform → In-line |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-09-09 | 개시 | SVB Leerink | Mkt Perform |
| 2021-01-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2020-11-24 | 개시 | Evercore ISI | Underperform |
| 2020-08-28 | 재개 | ROTH Capital | Buy |
| 2020-08-26 | 개시 | Piper Sandler | Overweight |
| 2020-07-27 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2020-03-17 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2019-11-22 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-26 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2019-05-24 | 개시 | Wolfe Research | Outperform |
| 2019-04-23 | 업그레이드 | Berenberg | Hold → Buy |
| 2018-12-13 | 개시 | Berenberg | Hold |
| 2018-06-06 | 개시 | ROTH Capital | Buy |
| 2018-02-08 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-01-02 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2017-11-21 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2017-07-11 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2016-04-28 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | 재확인 | Barclays | Underweight |
| 2015-10-23 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2015-10-23 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
모두보기
Enanta Pharmaceuticals Inc 주식(ENTA)의 최신 뉴스
How Enanta Pharmaceuticals Inc. stock compares to growth peersMarket Volume Report & AI Enhanced Trading Alerts - newser.com
Using Ichimoku Cloud for Enanta Pharmaceuticals Inc. technicals2025 Geopolitical Influence & Weekly Top Performers Watchlists - newser.com
Tools to assess Enanta Pharmaceuticals Inc.’s risk profileStock Surge & Free Technical Confirmation Trade Alerts - newser.com
Why Enanta Pharmaceuticals Inc. (9EP) stock gets analyst attentionQuarterly Market Summary & Weekly Chart Analysis and Guides - newser.com
Why Enanta Pharmaceuticals Inc. stock is rated strong buyWeekly Investment Report & Precise Swing Trade Entry Alerts - newser.com
How to forecast Enanta Pharmaceuticals Inc. trends using time seriesJuly 2025 Rallies & Long-Term Investment Growth Plans - newser.com
Will breakout in Enanta Pharmaceuticals Inc. lead to full recoveryJuly 2025 Analyst Calls & Weekly Stock Breakout Alerts - newser.com
Is Enanta Pharmaceuticals Inc. stock ready for a breakoutJuly 2025 Setups & AI Enhanced Trading Signals - newser.com
How Enanta Pharmaceuticals Inc. stock performs in rising dollar environmentWall Street Watch & Risk Adjusted Buy/Sell Alerts - newser.com
Can Enanta Pharmaceuticals Inc. (9EP) stock deliver strong annual returnsTrade Volume Report & Growth Oriented Trade Recommendations - newser.com
Is Enanta Pharmaceuticals Inc. stock a good choice for value investorsStock Surge & Stock Portfolio Risk Control - newser.com
How Enanta Pharmaceuticals Inc. stock benefits from strong dollar2025 Market Trends & Verified Entry Point Signals - newser.com
Will earnings trigger a reversal in Enanta Pharmaceuticals Inc.2025 Big Picture & Daily Stock Trend Watchlist - newser.com
Is Enanta Pharmaceuticals Inc. stock positioned well for digital economyTrade Volume Summary & Fast Moving Market Watchlists - newser.com
How reliable is Enanta Pharmaceuticals Inc. (9EP) stock dividend growth2025 Analyst Calls & Technical Pattern Alert System - newser.com
What the charts say about Enanta Pharmaceuticals Inc. todayWeekly Profit Recap & Safe Entry Trade Reports - newser.com
What drives Enanta Pharmaceuticals Inc 9EP stock priceStraddle and Strangle Trades & Lower Drawdowns With Smart Position Sizing - earlytimes.in
Is Enanta Pharmaceuticals Inc. stock supported by strong cash flowsWeekly Earnings Recap & Weekly Return Optimization Alerts - newser.com
How institutional buying supports Enanta Pharmaceuticals Inc. stockQuarterly Trade Report & Growth Focused Entry Reports - newser.com
Can Enanta Pharmaceuticals Inc. stock resist market sell offsDip Buying & Safe Swing Trade Setups - newser.com
Is Enanta Pharmaceuticals Inc. stock attractive for retirement portfoliosDay Trade & Stepwise Swing Trade Plans - newser.com
How to use a screener to detect Enanta Pharmaceuticals Inc. breakoutsWeekly Gains Report & Risk Controlled Stock Pick Alerts - newser.com
Trend analysis for Enanta Pharmaceuticals Inc. this weekJuly 2025 Catalysts & Smart Swing Trading Alerts - newser.com
How Enanta Pharmaceuticals Inc. stock compares to industry benchmarksWeekly Trade Review & Community Consensus Stock Picks - newser.com
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Not Doing Enough For Some Investors As Its Shares Slump 30% - simplywall.st
Enanta Pharmaceuticals Inc (ENTA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.68%
0.96%
자본화:
|
볼륨(24시간):